Get the Stockscreener App
10.50
32.82%
-5.13
Pre-market:
9.71
-0.79
-7.52%
Uniqure N V stock is traded at $10.50, with a volume of 16.76M.
It is down -32.82% in the last 24 hours and down -57.49% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$15.63
Open:
$9.19
24h Volume:
16.76M
Relative Volume:
6.18
Market Cap:
$654.06M
Revenue:
$15.75M
Net Income/Loss:
$-235.15M
P/E Ratio:
-2.394
EPS:
-4.386
Net Cash Flow:
$-154.09M
1W Performance:
-57.08%
1M Performance:
-57.49%
6M Performance:
-38.27%
1Y Performance:
-20.15%
1-Day Range:
$8.96
$11.09
1-Week Range:
$8.96
$25.13
52-Week Range:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
10.50 | 973.62M | 15.75M | -235.15M | -154.09M | -4.386 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Morningstar
uniQure (QURE) Shares Affected by FDA Commentary - GuruFocus
Stifel comments on uniQure shares after FDA commissioner remarks By Investing.com - Investing.com India
uniQure (QURE) Faces Investor Concerns Amid FDA Commentary - GuruFocus
uniQure (NASDAQ:QURE) Shares Gap DownShould You Sell? - MarketBeat
uniQure down on FDA chief's comments (update) (QURE:NASDAQ) - Seeking Alpha
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
uniQure (QURE) Shares Plunge as FDA Casts Doubt on AMT-130 Approval - GuruFocus
uniQure N.V. Stock Alert: QURE Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses - PR Newswire
UniQure stock tumbles on FDA comments about gene therapy trial - Investing.com
INVESTOR REMINDER: Berger Montague Notifies uniQure N.V. (QURE) Investors of a Class Action Lawsuit and Deadline - marketscreener.com
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. ... - Bluefield Daily Telegraph
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm - GlobeNewswire Inc.
QURE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
QURE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 (2026-02-25) - Seeking Alpha
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler - GlobeNewswire
UNIQURE N.V. (QURE) DEADLINE ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - ACCESS Newswire
uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co. - MarketBeat
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
BellRing Brands, Inc. Securities Fraud Class Action Result of Inventory Issues and 52% Stock Decline - GlobeNewswire Inc.
QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm - PR Newswire
QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
The Gross Law Firm Reminds uniQure Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - Morningstar
Wolfe Research Initiates Coverage on uniQure (QURE) with 'Peer P - GuruFocus
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Wolfe Research Initiates Coverage of uniQure N.V. (QURE) with Peer Perform Recommendation - Nasdaq
5 Analysts Assess uniQure: What You Need To Know - Benzinga
Holzer & Holzer, LLC Reminds QURE Investors of the April - GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages uniQure N.V. - GlobeNewswire
Shareholders that lost money on uniQure N.V.(QURE) Urged to - GlobeNewswire
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action LawsuitContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Quarterly Risk: Can uniQure NV continue delivering strong returns - baoquankhu1.vn
uniQure to Announce 2025 Financial Results - The Manila Times
uniQure N.V. to Report Q4 and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
UniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsQURE - marketscreener.com
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit – Company Announcement - Financial Times
User - The Chronicle-Journal
QURE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
uniQure (NASDAQ:QURE) Stock Price Down 5.8% – Should You Sell? - Defense World
Will uniQure N.V. stock recover faster than marketPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Avoro Capital Advisors LLC Increases Stake in uniQure NV - GuruFocus
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - Sahm
RTW INVESTMENTS, LP Reduces Stake in uniQure NV - GuruFocus
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):